1. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation 2021;143:e254–e743.
2. Kim JH, Chae SC, Oh DJ, et al. Multicenter cohort study of acute myocardial infarction in Korea: interim analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry. Circ J 2016;80:1427–1436.
3. Ulvenstam G, Aberg A, Bergstrand R, et al. Recurrent myocardial infarction. 1. Natural history of fatal and non-fatal events. Eur Heart J 1985;6:294–302.
4. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020–2035.
6. World Health Organization. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney (AU): World Health Organization, 2000;17–18.
7. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008;29:932–940.
8. Park HW, Yoon CH, Kang SH, et al. Early- and late-term clinical outcome and their predictors in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction. Int J Cardiol 2013;169:254–261.
9. Yudi MB, Clark DJ, Farouque O, et al. Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention. Am Heart J 2019;212:134–143.
10. Thune JJ, Signorovitch JE, Kober L, et al. Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. Eur J Heart Fail 2011;13:148–153.
12. Nakatani D, Sakata Y, Suna S, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J 2013;77:439–446.
14. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(12 Suppl):S16–S23.
15. Bauters C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998;31:1291–1298.
17. Wihanda D, Alwi I, Yamin M, Shatri H, Mudjaddid E. Factors associated with in-stent restenosis in patients following percutaneous coronary intervention. Acta Med Indones 2015;47:209–215.
18. Sukhija R, Aronow WS, Sureddi R, et al. Predictors of in-stent restenosis and patient outcome after percutaneous coronary intervention in patients with diabetes mellitus. Am J Cardiol 2007;100:777–780.
19. Goldberg SL, Loussararian A, De Gregorio J, Di Mario C, Albiero R, Colombo A. Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol 2001;37:1019–1025.
20. Claessen BE, Smits PC, Kereiakes DJ, et al. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus-versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovasc Interv 2011;4:1209–1215.
24. Suzuki K, Oikawa T, Nochioka K, et al. Elevated serum non-HDL (high-density lipoprotein) cholesterol and triglyceride levels as residual risks for myocardial infarction recurrence under statin treatment. Arterioscler Thromb Vasc Biol 2019;39:934–944.
25. Gallone G, Baldetti L, Pagnesi M, et al. Medical therapy for long-term prevention of atherothrombosis following an acute coronary syndrome: JACC state-of-the-art review. J Am Coll Cardiol 2018;72(23 Pt A):2886–2903.